Tecentriq/Cotellic combo fails in Phase III for third-line colorectal cancer

Roche (SIX:ROG; OTCQB:RHHBY) and partner Exelixis Inc. (NASDAQ:EXEL) said Tecentriq atezolizumab plus Cotellic cobimetinib missed the primary endpoint of improving overall survival (OS) vs. Stivarga regorafenib in the Phase III IMblaze370 trial as third-line treatment of colorectal

Read the full 374 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE